[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Tuesday, 22 May 2007, 10:39 GMT 11:39 UK
Indians buy Israeli drug company
A selection of generic drugs
Taro and Sun both specialise in generic pharmaceuticals
India's Sun Pharmaceuticals is buying Israel's Taro Pharmaceutical Industries for $454m (230m).

More than 90% of Taro's sales are in North America and Sun hopes the acquisition will strengthen its own sales there.

India and Israel are big manufacturers of generic drugs, which are treatments whose patents have expired.

The generic drug market is growing at twice the rate of patented drugs as blockbusters lose their protection.

The deal is India's second-largest acquisition in the drugs industry, after the $570m takeover of Germany's Betapharm by Hyderabad-based Dr Reddy's Laboratories last year.

Another generic drug company, Ranbaxy, is one of India's most acquisitive companies, having bought eight rivals last year.

Court ruling

Two of Taro's shareholders, Franklin Advisers and Templeton Asset Management, tried to block the deal.

They went to court in Tel Aviv to seek an injunction on the grounds that the deal was not in the interests of minority shareholders.

But the court decided not to issue the injunction, although there was a deal done with Taro, which agreed to reduce its interim funding.

Sun makes generic drugs specialising in areas such as psychiatry, neurology and cardiology.

Taro specialises in dermatology and paediatrics.




SEE ALSO
Clinton unveils Aids drugs deal
09 May 07 |  Americas
India's Dr Reddy's buys Betapharm
16 Feb 06 |  Business
Indian drug maker buys UK firms
13 Mar 02 |  Business

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites



FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific